title: Response to comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.
authors.affiliation: Corresponding author: Edwin A.M. Gale, edwin.gale@bristol.ac.uk.
authors.forename: Edwin A M
authors.initials: EA
authors.lastname: Gale
mesh_terms: D000818:Animals; D006801:Humans; D054795:Incretins / Q000627:therapeutic use*
chemical_list: D054795:Incretins